GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » LT-Debt-to-Total-Asset

Nanopharmaceutics (Nanopharmaceutics) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2018)


View and export this data going back to 2016. Start your Free Trial

What is Nanopharmaceutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nanopharmaceutics's long-term debt to total assests ratio for the quarter that ended in Sep. 2018 was 0.00.

Nanopharmaceutics's long-term debt to total assets ratio stayed the same from Sep. 2017 (0.00) to Sep. 2018 (0.00).

Nanopharmaceutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Nanopharmaceutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanopharmaceutics LT-Debt-to-Total-Asset Chart

Nanopharmaceutics Annual Data
Trend Dec15 Dec16 Dec17
LT-Debt-to-Total-Asset
- 0.02 0.01

Nanopharmaceutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - 0.01 0.01 0.01 -

Nanopharmaceutics LT-Debt-to-Total-Asset Calculation

Nanopharmaceutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2017 is calculated as

LT Debt to Total Assets (A: Dec. 2017 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2017 )/Total Assets (A: Dec. 2017 )
=0.009/0.666
=0.01

Nanopharmaceutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2018 is calculated as

LT Debt to Total Assets (Q: Sep. 2018 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2018 )/Total Assets (Q: Sep. 2018 )
=0/0.714
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanopharmaceutics  (OTCPK:TGRP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nanopharmaceutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Nanopharmaceutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanopharmaceutics (Nanopharmaceutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanopharmaceutics Inc (OTCPK:TGRP) » Definitions » LT-Debt-to-Total-Asset
Comparable Companies
MIII TSE:5363 TSE:7721 TSE:5821 TSX:AEF SDOIA DFM:GGICO SAU:2120 ABWN COL:RICH.N0000 CNAC MIL:SPRT XSGO:QUEMCHI TSE:3353 COL:VONE.N0000 XPAE:APIC MIL:CRS ELEC ATH:MIG XCNQ:MARI
Traded in Other Exchanges
N/A
Address
14120 NW 126 Terrace, Alachua, FL, USA, 32615
Website
https://www.nanopharmaceutics.com
Nanopharmaceutics Inc is a clinical-stage specialty pharmaceutical company. It is engaged in developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The company's pipeline products include Triapine, Ammonium Tetrathiomolybdate, and Aza-TdC targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3 targeting CNS; and Ramoplanin and NanoDOX.